Skip to Content

Clindamycin / tretinoin topical Pregnancy and Breastfeeding Warnings

Clindamycin / tretinoin topical is also known as: Veltin, Ziana

Medically reviewed on Jul 10, 2018

Clindamycin / tretinoin topical Pregnancy Warnings

Animal studies have failed to reveal evidence of teratogenicity (clindamycin). Animal studies have revealed teratogenicity, embryotoxicity and increased abortion rates (tretinoin). There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended in pregnancy, especially during the first trimester, and in women of childbearing potential.

US FDA pregnancy category: C

See references

Clindamycin / tretinoin topical Breastfeeding Warnings

Oral and parenteral administration of clindamycin has been reported to appear in breast milk. Additionally, orally administered retinoids and their metabolites have been reported to be secreted in breast milk.

Use is not recommended.

Excreted into human milk: Unknown (clindamycin, tretinoin)
Excreted into animal milk: Data not available (clindamycin, tretinoin)

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Ziana (clindamycin-tretinoin topical)." Medicis Pharmaceutical Corporation, Scottsdale, AZ.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Ziana (clindamycin-tretinoin topical)." Medicis Pharmaceutical Corporation, Scottsdale, AZ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide